Aldeyra Therapeutics
ALDX
103 hedge funds and large institutions have $117M invested in Aldeyra Therapeutics in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 16 closing their positions.
395% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $219K
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
1% more funds holding
Funds holding: 102 → 103 (+1)
1% more capital invested
Capital invested by funds: $116M → $117M (+$1.05M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.67% less ownership
Funds ownership: 60.15% → 59.47% (-0.67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.67M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.08M |
| 3 |
PI
PFG Investments
Woodbury,
New York
|
+$1.55M |
| 4 |
BlackRock
New York
|
+$1.22M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.82M |
| 2 |
Millennium Management
New York
|
-$1.35M |
| 3 |
D.E. Shaw & Co
New York
|
-$884K |
| 4 |
Renaissance Technologies
New York
|
-$879K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$823K |
ALDX Hedge Fund Activity: Q2 2024 in Review
103 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2024, worth a combined $117M — up 0.91% from $116M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALDX positions and 16 closed out — a net gain of 2 holders — while 34 added to existing stakes and 32 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $2.67M. The largest seller was Verition Fund Management, cutting an estimated $2.82M.
- 103 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2024, up from 102 in Q1 2024.
- Funds reported $117M of Aldeyra Therapeutics stock for Q2 2024, up 0.91% quarter-over-quarter.
- 18 funds opened new Aldeyra Therapeutics positions in Q2 2024 and 16 closed out, a net change of +2 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2024 was Perceptive Advisors, an estimated $2.67M added.
- The largest Aldeyra Therapeutics seller in Q2 2024 was Verition Fund Management, an estimated $2.82M sold.
Based on aggregated 13F filings for Q2 2024.